Sonoma pharmaceuticals reports fiscal year and fourth quarter 2022 financial results

Revenues increased 7% in q4 2022 compared to q4 2021 net loss per share improved quarter over quarter and year over year strong balance sheet with $7.4 million of cash woodstock, ga / accesswire / july 13, 2022 / sonoma pharmaceuticals, inc. (nasdaq:snoa),a global healthcare leader developing and producing patented microcyn® technology-based stabilized hypochlorous acid (hocl) products for a wide range of applications including wound, eye, oral and nasal care and dermatological conditions, today announced financial results for fiscal year 2022 and the fourth quarter ended march 31, 2022. "our fourth quarter continues to reflect the restructuring and transition from sonoma's last two years," commented amy trombly, ceo of sonoma.
SNOA Ratings Summary
SNOA Quant Ranking